Purpose High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
(HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to …

High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (HGBL-
DH/THs) include a group of diffuse large B-cell lymphomas (DLBCLs) with inferior outcomes …

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-
DH/TH) is a newly defined entity in the latest World Health Organization Classification …

High-grade B-cell lymphomas (HGBLs) with MYC and BCL2 and/or BCL6 rearrangements,
so-called “double-hit” lymphomas (HGBL-DH), are aggressive lymphomas that form a …

Double-hit B-cell lymphoma is a common designation for a group of tumors characterized by
concurrent translocations of MYC and BCL2, BCL6, or other genes. The prognosis of …

Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …

Personalized therapy for the treatment of patients with cancer is rapidly approaching and is
an achievable goal in the near future. A substantial number of novel targets have been …

Molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) underlies the variable
outcomes achieved with immunochemotherapy. However, outcomes of gene expression …

Purpose: We have previously shown the prognostic significance of BCL2 expression in the
activated B-cell–like diffuse large B-cell lymphoma (ABC-DLBCL) patients treated with …

Background The poor outcome of high-grade B-cell lymphoma, with rearrangements of
MYC, BCL2 and/or BCL6, also known as double-hit lymphoma or triple-hit lymphoma (DHL …